Brokerages expect that Invuity, Inc. (NASDAQ:IVTY) will post sales of $9.58 million for the current quarter, Zacks reports. Four analysts have provided estimates for Invuity’s earnings, with estimates ranging from $9.50 million to $9.80 million. Invuity posted sales of $9.02 million during the same quarter last year, which suggests a positive year over year growth rate of 6.2%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, April 25th.
According to Zacks, analysts expect that Invuity will report full year sales of $9.58 million for the current financial year, with estimates ranging from $45.60 million to $46.40 million. For the next fiscal year, analysts anticipate that the firm will report sales of $56.00 million per share, with estimates ranging from $53.40 million to $58.10 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Invuity.
Invuity (NASDAQ:IVTY) last issued its quarterly earnings data on Tuesday, February 13th. The medical instruments supplier reported ($0.43) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.07. Invuity had a negative return on equity of 380.14% and a negative net margin of 100.75%. The company had revenue of $11.23 million during the quarter, compared to the consensus estimate of $11.84 million.
Institutional investors have recently made changes to their positions in the business. BlueCrest Capital Management Ltd acquired a new stake in Invuity in the fourth quarter valued at approximately $139,000. Eversept Partners LLC acquired a new stake in Invuity in the fourth quarter valued at approximately $279,000. Wells Fargo & Company MN grew its stake in Invuity by 987.0% in the fourth quarter. Wells Fargo & Company MN now owns 64,198 shares of the medical instruments supplier’s stock valued at $398,000 after acquiring an additional 58,292 shares during the period. Vanguard Group Inc. grew its stake in Invuity by 16.3% in the second quarter. Vanguard Group Inc. now owns 402,680 shares of the medical instruments supplier’s stock valued at $2,919,000 after acquiring an additional 56,527 shares during the period. Finally, Millennium Management LLC grew its stake in Invuity by 26.5% in the fourth quarter. Millennium Management LLC now owns 418,116 shares of the medical instruments supplier’s stock valued at $2,592,000 after acquiring an additional 87,587 shares during the period. 63.59% of the stock is owned by hedge funds and other institutional investors.
Invuity (IVTY) traded up $0.18 during midday trading on Thursday, reaching $4.40. The company had a trading volume of 85,709 shares, compared to its average volume of 193,953. Invuity has a fifty-two week low of $3.30 and a fifty-two week high of $9.70. The company has a quick ratio of 2.47, a current ratio of 2.55 and a debt-to-equity ratio of -33.85.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3256175/invuity-inc-ivty-expected-to-announce-quarterly-sales-of-9-58-million-2.html.
Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.